NCT07288294

Brief Summary

The goal of this clinical trial pilot is to determine the feasibility of an intervention to enhance weight management in patients who have stopped taking anti-obesity/weight management medications in primary care. The main questions it aims to answer are:

  • Can patients be recruited into the study efficiently?
  • Is the program acceptable to patients?
  • Can the study be conducted efficiently? The new program will be compared to usual care.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
214

participants targeted

Target at P75+ for not_applicable obesity

Timeline
20mo left

Started Jun 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
Jun 2026Apr 2028

First Submitted

Initial submission to the registry

November 14, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 17, 2025

Completed
6 months until next milestone

Study Start

First participant enrolled

June 4, 2026

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2028

Last Updated

July 9, 2026

Status Verified

July 1, 2026

Enrollment Period

1.8 years

First QC Date

November 14, 2025

Last Update Submit

July 7, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Recruitment rate

    The recruitment rate will be defined as the number of participants randomized into the clinical trial per month.

    Baseline

  • Acceptability of the Intervention

    Self-reported Likert scale items will assess the overall satisfaction with the program, the likelihood participants would recommend the program to others, and their satisfaction with individual treatment components (e.g., the online check-ins).

    3 and 6 months post randomization

Secondary Outcomes (2)

  • Medication adherence duration questions

    From consent to reported discontinuation, up to 22 months

  • Reasons for Discontinuation questions

    Baseline

Other Outcomes (9)

  • Recruitment efficiency

    Baseline

  • Retention to the study

    6 months post-randomization

  • Intervention adherence

    Randomization to 6 months

  • +6 more other outcomes

Study Arms (2)

PRISM Program

EXPERIMENTAL

This is a novel, remotely delivered, self-tailored intervention for post-anti-obesity medication discontinuation weight management.

Behavioral: PRISM Program

Usual Care

NO INTERVENTION

Participants will continue to receive their regular, usual primary care.

Interventions

PRISM ProgramBEHAVIORAL

This is a novel, remotely delivered, self-tailored intervention for post-anti-obesity medication discontinuation weight management. The program incorporates standard-of-care behavioral intervention strategies for weight control to improve routine self-weighing, dietary self-monitoring, and increasing physical activity. The program includes an enhanced focus on strategies to reduce food cue reactivity. The program includes six monthly one-on-one sessions between study staff and participants, asynchronous online check-ins weekly for 12 weeks, and bi-weekly for 12 weeks.

PRISM Program

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • For run-in: prescribed liraglutide, semaglutide, or tirzepatide or newer medication approved by the FDA for long-term use for obesity treatment for the purpose of weight managment by a primary care provider at Rush University System for Health and have received at least one dose of the medication concurrent with enrollment in the study.
  • For randomization: discontinue their prescribed anti-obesity medication.
  • Age 18+

You may not qualify if:

  • Not fluent in English
  • Diagnosis of diabetes (type 1 or type 2)
  • Current or planned pregnancy
  • Bariatric surgery in the past 2 years or planned bariatric surgery.
  • Body mass index ≥60 kg/m2, due to increased injury risk with exercise
  • Body weight ≥ 375 pounds (scale capacity with a margin for regain)
  • No access to home WIFI or a smartphone with data available
  • Medical contraindications to treatment, including significant cognitive impairment, active substance abuse based on the World Health Organization's ASSIST screener, or serious medical illness (e.g., stage 3 or 4 heart failure, cancer, renal failure, etc.)
  • Concurrent engagement with other behavioral treatments for obesity (for randomized phase only).
  • Medication obtained from online/compound pharmacies or prescription from specialty clinic without a prescription from primary care team at the time of enrollment
  • Another member of the household is enrolled in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rush University Medical Center

Chicago, Illinois, 60130, United States

RECRUITING

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Melissa M Crane, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This project is a randomized feasibility study with a run-in period
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 14, 2025

First Posted

December 17, 2025

Study Start

June 4, 2026

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

April 1, 2028

Last Updated

July 9, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will share

Locations